TalkMed's (SGX:5G3) attributable profit to owners jumped 90% during the second half of 2024 to SG$34.0 million from SG$17.9 million a year earlier, according to a filing with the Singapore Exchange on Tuesday.
Earnings per share rose to SG$0.0254 compared with SG$0.0134 in the comparable period.
Revenue declined 2% year over year to SG$45.1 million from SG$46.0 million, due to a decrease in revenue from the oncology services segment.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。